

Strides Pharma Global (UK) Limited (Formerly Strides Pharma (UK) Limited)
BALANCE SHEET AS AT MARCH 31, 2017

	Note No.	31-Mar-17	GBP 31-Mar-16
A ASSETS			
I Non-current assets			
(a) Financial assets			
(i) Investments		24,940,352	40,493,840
Total Non-current assets		<u>24,940,352</u>	<u>40,493,840</u>
II Current assets			
(a) Financial assets			
(i) Cash and cash equivalents	1	4,474	-
(ii) Other financials assets	2	1,818,326	1,080,757
Total Current assets		<u>1,822,800</u>	<u>1,080,757</u>
Total Assets		<u><u>26,763,151</u></u>	<u><u>41,574,597</u></u>
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity Share capital	3	43,357,438	43,357,338
(b) Other equity	4	(19,877,169)	(3,703,009)
Total Equity		<u>23,480,269</u>	<u>39,654,329</u>
II Liabilities			
1 Current liabilities			
(a) Financials Liabilities			
(i) Trade payables	5	6,120	-
(b) Other current liabilities	6	3,276,762	1,920,267
		<u>3,282,882</u>	<u>1,920,267</u>
Total Equity and liabilities		<u><u>26,763,151</u></u>	<u><u>41,574,597</u></u>

See accompanying notes forming part of the Financial Statements

Strides Pharma Global (UK) Limited (Formerly Strides Pharma (UK) Limited)
STATEMENT OF PROFIT AND LOSS
FOR THE PERIOD ENDED MARCH 31, 2017

	Note No.	31-Mar-17	31-Mar-16
1 Revenue from operations		-	-
2 Other income	7	415	-
3 Total revenue (1+2)		415	-
4 Expenses			
(a) Cost of materials consumed		-	-
(b) Purchase of stock-in-trade		-	-
(c) (Increase) / Decrease in inventories of finished goods, work-in-progress and stock-in-trade		-	-
(a) Employee benefits expenses		-	-
(b) Other expenses	8	3,060	-
Total		3,060	-
5 Earning before exceptional items, interest, tax, depreciation and amortisation (EBITDA) (3-4)		(2,645)	-
6 Finance costs	9	3,415	-
7 Depreciation and amortisation expense		-	-
8 Profit before exceptional items and tax (5-6-7)		(6,060)	-
9 Exceptional items gain / (loss) (net)		(44,498)	(59,571)
10 Profit before tax (8+9)		(50,559)	(59,571)
11 Tax expense		-	-
12 Profit for the year (10-11)		(50,559)	(59,571)
13 Other Comprehensive Income			
A) (i) Items that will not be reclassified to profit or loss		(16,123,601)	(3,643,438)
A) (ii) Income tax relating to items that will not be reclassified to profit or loss		-	-
B) (i) Items that may be reclassified to profit or loss		-	-
B) (ii) Income tax relating to items that may be reclassified to profit or loss		-	-
Total Other comprehensive Income		(16,123,601)	(3,643,438)
14 Total Comprehensive Income for the period (12+13)		(16,174,160)	(3,703,009)

See accompanying notes forming part of the Financial Statements

Strides Pharma Global (UK) Limited (Formerly Strides Pharma (UK) Limited)
Notes forming part of the financial statements

Note

No.

1 Cash and cash equivalents	GBP	
Particulars	31-Mar-17	31-Mar-16
Cash in hand	-	-
Balance with banks in current account	4,474	-
Total	4,474	-

2 Other financial assets	GBP	
Particulars	31-Mar-17	31-Mar-16
Loans and advances to related party	1,818,077	1,080,757
Others	249	-
Total	1,818,326	1,080,757

5 Trade payables	GBP	
Particulars	31-Mar-17	31-Mar-16
Other than acceptances	6,120	-
Total	6,120	-

6 Other current liabilities	GBP	
Particulars	31-Mar-17	31-Mar-16
Payable to related parties	3,276,762	1,920,267
Total	3,276,762	1,920,267

Strides Pharma Global (UK) Limited (Formerly Strides Pharma (UK) Limited)
STATEMENT OF CHANGES IN EQUITY

3 Share capital

GBP

Particulars	31-Mar-17	31-Mar-16
Authorised		
Total	-	-
Issued, subscribed and fully paid-up		
Equity	22,086,538	22,086,438
Preference	21,270,900	21,270,900
Total	43,357,438	43,357,338

Strides Pharma Global (UK) Limited (Formerly Strides Pharma (UK) Limited)
STATEMENT OF CHANGES IN EQUITY

4 Other equity	GBP	
Particulars	31-Mar-17	31-Mar-16
Securities Premium Account		
Opening Balance	-	-
Add : Premium on shares issued during the year	-	-
Closing balance	-	-
Surplus in Statement of Profit and Loss		
Opening Balance	(59,571)	-
Add: (Loss) for the year	(50,559)	(59,571)
Closing balance	(110,130)	(59,571)
Share application monies pending allotment		
Opening Balance	-	-
Add : Monies received during the year	-	-
Less : Share issued/money refunded during the year	-	-
Closing balance	-	-
Other comprehensive income		
Actuarial gain/(loss) on defined benefit obligation		
Opening Balance	(3,643,438)	-
Add/(less): Other comprehensive income for the year	(16,123,601)	(3,643,438)
Add/(less): Tax impact on the above	-	-
Closing balance	(19,767,039)	(3,643,438)
Total	(19,877,169)	(3,703,009)

Strides Pharma Global (UK) Limited (Formerly Strides Pharma (UK) Limited)
Notes forming part of the financial statements

Note

No.

7 Other income	GBP	
Particulars	31-Mar-17	31-Mar-16
Exchange fluctuation gain (net)	415	-
Total	415	-

8 Other expenses	GBP	
Particulars	31-Mar-17	31-Mar-16
Legal and Professional fees	3,060	-
Total	3,060	-

9 Finance cost	GBP	
Particulars	31-Mar-17	31-Mar-16
Interest expenses	-	-
Bank Charges & Commission	3,415	-
Total	3,415	-